Vandervoort Adam C 4
4 · Teladoc Health, Inc. · Filed Jun 3, 2026
Research Summary
AI-generated summary of this filing
Teladoc (TDOC) Chief Legal Officer Adam Vandervoort Sells Shares
What Happened Adam C. Vandervoort, Teladoc Health’s Chief Legal Officer and Secretary, had restricted and performance awards convert into 14,928 shares on June 1, 2026 (three conversion/exercise entries: 426, 5,350 and 9,152 shares). Following conversion, 7,906 shares were sold in an open‑market transaction on June 2, 2026 at $7.63 per share for gross proceeds of $60,299. The filing shows certain shares were treated as derivative dispositions at $0 — consistent with shares being used to satisfy tax withholding or otherwise retained/withheld in connection with the vesting/conversion.
Key Details
- Transaction dates: conversions/exercises on 2026-06-01; open‑market sale on 2026-06-02.
- Sale: 7,906 shares at $7.63 for $60,299 total.
- Converted/received: 14,928 shares (426 + 5,350 + 9,152) on 2026-06-01.
- Shares shown as disposed at $0 reflect withholding/transfer in connection with conversion/vesting (per footnote).
- Footnotes: F1/F2 – PSUs and RSUs convert 1:1 to TDOC common stock. F3 – shares sold to cover tax withholding related to vesting. F4–F7 describe vesting schedules/grants underlying the awards (including PSU earned 3/1/2026 and RSU grants from 3/19/2024 and 3/1/2025).
- Shares owned after the transaction are not disclosed in the filing.
- Filing date: 2026-06-03 (timely; Form 4 filed within the normal two-business-day window).
Context
- The M transaction code indicates exercise/conversion of derivative awards (here, PSUs/RSUs converting to common shares). The subsequent open‑market sale appears primarily to cover tax withholding obligations tied to the vesting/conversion (a common, routine action), rather than a standalone investment judgment. This filing does not necessarily indicate a broader change in insider sentiment.
Insider Transaction Report
- Exercise/Conversion
Common Stock
[F1]2026-06-01+426→ 103,665 total - Exercise/Conversion
Common Stock
[F2]2026-06-01+5,350→ 109,015 total - Exercise/Conversion
Common Stock
[F2]2026-06-01+9,152→ 118,167 total - Sale
Common Stock
[F3]2026-06-02$7.63/sh−7,906$60,299→ 110,261 total - Exercise/Conversion
Performance Stock Units
[F1][F4][F5]2026-06-01−426→ 2,979 total→ Common Stock (426 underlying) - Exercise/Conversion
Restricted Stock Units
[F2][F6]2026-06-01−5,350→ 16,050 total→ Common Stock (5,350 underlying) - Exercise/Conversion
Restricted Stock Units
[F2][F7]2026-06-01−9,152→ 64,070 total→ Common Stock (9,152 underlying)
Footnotes (7)
- [F1]Performance stock units convert to shares of TDOC common stock on a one-for-one basis.
- [F2]Restricted stock units convert to shares of TDOC common stock on a one-for-one basis.
- [F3]Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance stock unit and restricted stock unit awards.
- [F4]The performance stock units vest as to one-third on March 1, 2026, with the remainder vesting in eight substantially equal quarterly installments thereafter.
- [F5]On March 1, 2026, the reporting person earned 5,107 performance stock units, vesting one-third on March 1, 2026, with the remainder vesting in eight substantially equal quarterly installments thereafter.
- [F6]On March 19, 2024, the reporting person was granted 64,200 restricted stock units, vesting one-third on the first anniversary of the grant date, with the remainder vesting in eight substantially equal quarterly installments beginning on June 1, 2025.
- [F7]On March 1, 2025, the reporting person was granted 109,832 restricted stock units, vesting one-third on March 1, 2026, with the remainder vesting in eight substantially equal quarterly installments thereafter.